To include your compound in the COVID-19 Resource Center, submit it here.

Delenex's DLX105 misses in psoriasis Phase II

Delenex Therapeutics AG (Zurich, Switzerland) said DLX105 led to no

Read the full 109 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE